PFG
RGNX icon

PAX Financial Group’s Regenxbio RGNX Stock Holding History

PAX Financial Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,507
Closed -$610K – 233
2023
Q2 		$610K Buy
30,507
+4,243
+16% +$81.7K 0.14% 134
2023
Q1 		$497K Buy
+26,264
New +$581K 0.12% 151

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAX Financial Group's RGNX Position: Q3 2023 in Review

PAX Financial Group sold out of Regenxbio (RGNX) in Q3 2023, closing a stake of 30,507 shares — an estimated $610K sold.

PAX Financial Group first reported a position in RGNX in Q1 2023 and held it in 2 quarters. The position peaked at $610K in Q2 2023. 159 funds tracked by Wall St. Rank hold RGNX as of Q3 2023.

  • PAX Financial Group reported no remaining Regenxbio position as of Q3 2023 after selling out during the quarter.
  • PAX Financial Group sold 30,507 Regenxbio shares in Q3 2023, an estimated $610K.
  • PAX Financial Group first reported a position in Regenxbio in Q1 2023 and held it in 2 quarters.
  • PAX Financial Group's Regenxbio position peaked at $610K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Regenxbio as of Q3 2023.

Based on PAX Financial Group's 13F filing for Q3 2023, filed 13 Nov 2023.